Evidence map›Paper›PMID 36795752›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2023

HIV-1 prehairpin intermediate inhibitors show efficacy independent of neutralization tier.

Benjamin N Bell, Theodora U J Bruun, Natalia Friedland, Peter S Kim

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Benjamin N BellDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305.ORCID 0000-0001-5356-0173
Theodora U J BruunSarafan ChEM-H, Stanford University, Stanford, CA 94305.
Natalia FriedlandSarafan ChEM-H, Stanford University, Stanford, CA 94305.
Peter S KimSarafan ChEM-H, Stanford University, Stanford, CA 94305.ORCID 0000-0001-6503-4541

Funding

Creating high-resolution, epitope-focused vaccinesDP1AI158125 · NIAID · STANFORD UNIVERSITY · PI KIM, PETER S · 2020 to 2024
$5.9M
Stanford ChEM-H Chemistry/Biology Interface Predoctoral Training ProgramT32GM139791 · NIGMS · STANFORD UNIVERSITY · PI Carolyn Bertozzi, Christine Jacobs-Wagner · 2021 to 2026
$2.4M
NIAID NIH HHS DP1 AI158125NIGMS NIH HHS T32 GM139791
6 · The paper itself

Abstract

HIV-1 strains are categorized into one of three neutralization tiers based on the relative ease by which they are neutralized by plasma from HIV-1-infected donors not on antiretroviral therapy; tier-1 strains are particularly sensitive to neutralization while tier-2 and tier-3 strains are increasingly difficult to neutralize. Most broadly neutralizing antibodies (bnAbs) previously described target the native prefusion conformation of HIV-1 Envelope (Env), but the relevance of the tiered categories for inhibitors targeting another Env conformation, the prehairpin intermediate, is not well understood. Here, we show that two inhibitors targeting distinct highly conserved regions of the prehairpin intermediate have strikingly consistent neutralization potencies (within ~100-fold for a given inhibitor) against strains in all three neutralization tiers of HIV-1; in contrast, best-in-class bnAbs targeting diverse Env epitopes vary by more than 10,000-fold in potency against these strains. Our results indicate that antisera-based HIV-1 neutralization tiers are not relevant for inhibitors targeting the prehairpin intermediate and highlight the potential for therapies and vaccine efforts targeting this conformation.

Indexed as

Broadly Neutralizing AntibodiesHIV-1HIV InfectionsAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesHumansNeutralization TestsAntibodies, NeutralizingBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusHIV Antibodies5-HelixHIV-1prehairpin intermediatetier-2 virustier-3 virus

Identifiers

PMID36795752
PMCPMC9974412

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.